Madhura Chatterjee ^1* Dr Saurabh Gupta ² Tanmoy Mukherjee ³ Deepak Parashar ⁴ Umesh Kumar ^5* Arindam Maitra ^1* KAUSHIK DAS ^1*

• ¹ National Institute of Biomedical Genomics (NIBMG), Calcutta, India
• ² GLA University, Mathura, Uttar Pradesh, India
• ³ The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
• ⁴ Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
• ⁵ Institute of Management Studies, Ghaziabad, Ghaziabad, India

Gynecological cancer, the most common form of cancers in women worldwide, initiates in the reproductive organs of females. More often, the common treatment measures, i.e. surgery, radiation, and medical oncology are found to be unsuccessful in the treatment of gynecological tumors. Emerging evidence indicates that extracellular vesicles (EVs) play a significant role in the pathogenesis of gynecological cancers by distinct mechanisms. The present review highlights how EVs contribute to the progression of different types of gynecological cancers such as cervical cancer, endometrial cancer, ovarian cancer, vaginal cancer, uterine sarcoma, gestational trophoblastic disease (GTD), and vulvar cancer. The primary focus is to understand how EVs' cargo alters the phenotypic response of the recipient cells, thereby contributing to the progression of the disease, thus can be considered as a prognostic and diagnostic biomarker. A brief discussion on the role of EVs in the diagnosis and prognosis of different gynecological cancer types is also highlighted. Targeting the biogenesis of the EVs, their inside cargo, and EVs uptake by the recipient cells could be a potential therapeutic approach in the treatment of gynecological cancer beside conventional therapeutic means.